Non-responders, and the honest state of the evidence about them
The mechanism is well described. The variance is not.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 15 of 68 of this archive, newest first.
The mechanism is well described. The variance is not.
Follow the resin, not the catalogue.
The evidence base is thin and the document says so, which is to its credit.
Reported from the sessions, and from the two hours afterwards.
Reported from the analysis, not from a warning notice.
Deamidation adds 0.98 daltons. On a low-resolution instrument at incretin molecular weights, that is inside the noise.
The route did not close because of a rule about peptides.
The observation that closes a facility is rarely the dramatic one.
Reported from the analysis, not from a warning notice.
Dose reduction is not withdrawal, and the trials that tested withdrawal cannot be read as testing it.
A badge asserts that something was tested. It does not assert what, when, on whose sample, by what method, or whether the lot on sale is the lot that was tested.
A proper account of an operation that existed, and of what closing it cost.
The route did not close because of a rule about peptides.
A reminder that a purity figure is the output of a method, and that methods differ.
Follow the resin, not the catalogue.
Higher doses of these molecules have been studied. In general they produced modest additional efficacy and disproportionate additional symptom burden, which is why the…
Chromatographic software does not integrate every fluctuation in the baseline. It applies a threshold, and the threshold changes the reported purity by amounts that matter…
A proper account of an operation that existed, and of what closing it cost.
The evidence base is thin and the document says so, which is to its credit.
Follow the resin, not the catalogue.
Efficacy was never the question in this appraisal. Duration of treatment was.
A document is only as good as the chain that connects it to the material, and most chains here are two or three links longer than the paperwork admits.
Mass and function are different endpoints and training affects them differently. Most coverage treats them as one.
The evidence base is thin and the document says so, which is to its credit.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Efficacy was never the question in this appraisal. Duration of treatment was.
Nothing on this page is difficult. It is simply unfamiliar, and unfamiliarity is what makes a weak certificate look like a strong one.
Head-to-head data exists for some of these comparisons and not for others. This piece says which.
The dose-response curve in this class flattens near its top. That has direct consequences for whether the final rung is worth climbing.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.